This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Metabolic Syndrome Observation on a Regional Basis (ORSA Umbria)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: July 2, 2009
Last updated: October 12, 2010
Last verified: October 2010
The aim of the study is to assess the prevalence of Metabolic Syndrome in Italy on a regional basis, defined according to NCEP/ATPIII Guidelines criteria.

Metabolic Syndrome

Study Type: Observational
Study Design: Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Osservatorio Regionale Sulla Sindrome metabolicA

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Prevalence of Metabolic Syndrome in Primary Care Population [ Time Frame: July 2009 - March 2010 ]
  • Concomitant presence of other CV risk factors [ Time Frame: July 2009 - March 2010 ]

Estimated Enrollment: 1600
Study Start Date: October 2009
Study Completion Date: October 2010
Primary Completion Date: October 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Primary care clinic

Inclusion Criteria:

  • Patient aged between 18 and 75 years
  • Signed Informed consent
  • Laboratory analysis (lipidic profile and glycemia) performed in the last year

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Patients enrolled in clinical studies which the aim is to evaluate the efficacy and/or tolerability of anti-hypertensive and/or lipid lowering drugs
  • Subjects with serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's successful participation in the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00933010

Foligno, Italy
Research Site
Perugia, Italy
Research Site
Terni, Italy
Sponsors and Collaborators
Study Chair: Mario Mangrella AstraZeneca S.p.A., R&D
Study Director: Raffaele Sabia AstraZeneca S.p.A., R&D
  More Information

Responsible Party: MC MD, AstraZeneca Identifier: NCT00933010     History of Changes
Other Study ID Numbers: NIS-CIT-DUM-2008/1
Study First Received: July 2, 2009
Last Updated: October 12, 2010

Keywords provided by AstraZeneca:
metabolic syndrome
waist circumference

Additional relevant MeSH terms:
Metabolic Syndrome X
Pathologic Processes
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases processed this record on September 21, 2017